The American Kidney Fund (AKF) is launching its Kidney Month campaign on March 1, 2026, to raise awareness about kidney disease affecting 1 in 7 American adults. The campaign emphasizes early detection and prevention through the 'Kidneys Count' initiative and encourages people to pledge to discuss kidney health with their doctors. AKF will host Kidney Action Week (March 2-5) featuring expert sessions on kidney disease management and treatment options.

Argenx announced positive Phase 3 ADAPT OCULUS study results for VYVGART in treating ocular myasthenia gravis, meeting its primary endpoint with statistically significant improvement in patient-reported outcomes. The company reported strong Q4 earnings of $8.02 per share (beating consensus of $6.02) and sales of $1.32 billion (surpassing consensus of $1.29 billion). The results support a planned FDA supplemental application to expand VYVGART's label into oMG treatment.

argenx announced positive Phase 3 results for VYVGART in ocular myasthenia gravis (oMG), meeting its primary endpoint with statistical significance (p=0.012). The study showed significant improvement in ocular symptoms including diplopia and ptosis compared to placebo. The company plans to submit a Supplemental Biologics License Application (sBLA) to the FDA to expand VYVGART's label into oMG, representing the first targeted treatment specifically evaluated for this indication.

The generalized myasthenia gravis (gMG) market is expected to grow significantly through 2034, driven by novel immunotherapies including FABHALTA (iptacopan) from Novartis, Descartes-08 from Cartesian Therapeutics, and Claseprubart from Dianthus Therapeutics. The 7MM had approximately 205,000 prevalent gMG cases in 2024, with increasing incidence projected. These emerging therapies represent a shift toward mechanism-driven treatments targeting refractory disease and improving long-term disease control.

The biotech sector rebounded strongly in 2025 as M&A activity surged, becoming a stabilizing force for small and mid-cap companies. With 57% of biopharma acquisitions involving smaller firms and $30.9 billion in deals, investor sentiment shifted from GLP-1 drugs toward cancer and autoimmune disease treatments, particularly next-generation CAR-T therapies. Looking ahead to 2026, analysts expect continued M&A activity and strategic partnerships, though risks remain including FDA staff turnover and an 'IPO air pocket' from the 2023-2024 downturn.

Argenx discontinued its Phase 3 UplighTED studies evaluating efgartigimod for thyroid eye disease after an Independent Data Monitoring Committee recommended stopping the trials for futility, despite a favorable safety profile.

Denali Therapeutics appointed Tim Van Hauwermeiren to its Board of Directors and announced the departure of Chief Medical Officer Carole Ho to Eli Lilly, with Peter Chin assuming the Acting Chief Medical Officer role.

Pharmaceutical company argenx presented clinical trial data demonstrating VYVGART's effectiveness in treating generalized myasthenia gravis across different patient subtypes, including seronegative patients, with promising results in symptom reduction and steroid use management.

Pharmaceutical company argenx reported positive phase 3 clinical trial results for VYVGART in treating generalized myasthenia gravis (gMG) patients who are AChR-Ab seronegative, demonstrating statistically significant improvements across multiple patient subtypes.

Pomerantz LLP is investigating potential securities fraud by argenx SE after the FDA issued an alert about serious risks associated with their Vyvgart Hytrulo product, causing the company's stock price to drop.

The global CIDP market is growing due to increased awareness, improved diagnostics, and demand for advanced treatments, with key players driving innovation in targeted biologic therapies despite challenges like high treatment costs and limited options for refractory cases.

Pomerantz LLP is investigating potential securities fraud by argenx SE after the FDA issued an alert about serious risks associated with their Vyvgart Hytrulo product, causing the company's stock price to drop.